Evidence map›Paper›PMID 36381768›Full record

ReviewCureus2022

Gold Nanoparticles in Cancer Therapeutics and Diagnostics.

Shrawani Kulkarni, Sunil Kumar, Sourya Acharya

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Shrawani KulkarniDepartment of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, IND.
Sunil KumarDepartment of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, IND.
Sourya AcharyaDepartment of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, IND.
Datta Meghe Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conventional treatment for cancer is done by chemotherapy, radiotherapy, and/or surgery, which work by inhibiting the growth of the rapidly dividing neoplastic cells and excision of the neoplastic tissue, respectively. These methods affect the healthy tissues along with the diseased ones, as chemotherapeutic agents often cause toxicity in the body and a variety of unfavorable side effects, which can highly impair bodily functions. Otherwise, while operating, there is the danger of some cancerous cells not being excised or unnecessary additional removal of healthy tissues, again causing the patient to lose some functionality of their body. The emerging field of nanotechnology helps to revolutionize imaging and therapeutic management in cancer. The use of metallic nanoparticles, especially those derived from an inert metal like gold, which has a great list of advantages such as high biocompatibility, non-toxicity, easy synthesis, and effective functionality, makes this innovative technology crucial for further propagation of this field. These nanoparticles have a dual function, i.e., helping in precise fluorescent bioimaging and drug delivery of potent medication to specific tissue sites without affecting the general area highly in a negative fashion. Thus, integrating these methods into current clinical practice would advance our methods for diagnostics as well as treatment while decreasing the stress on the patient, overall elevating medical practices.

Indexed as

cancerdiagnosticsdrug deliverygold nanoparticlesphotodynamic therapythermal ablation

Identifiers

PMID36381768
PMCPMC9643018
OpenAlexW4303876158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.